Disease · MONDO_0001247
social phobia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. social phobia. Diseases, record MONDO_0001247. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001247
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs40
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SERTRALINE HYDROCHLORIDE | CHEMBL1709 | Small molecule | Approval | DailyMed | 3 | 0 | 0 | Drugs and targets |
| VENLAFAXINE HYDROCHLORIDE | CHEMBL1201066 | Small molecule | Approval | DailyMed | 3 | 0 | 0 | Drugs and targets |
| PAROXETINE HYDROCHLORIDE | CHEMBL6067650 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| PAROXETINE MESYLATE | CHEMBL1200609 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| PAROXETINE | CHEMBL490 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| FASEDIENOL | CHEMBL5095042 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| CYCLOSERINE | CHEMBL771 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| SERTRALINE | CHEMBL809 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ESCITALOPRAM | CHEMBL1508 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
1 to 10 of 40
See all 40 drugsTargets64
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | 13 | Serotonin transporter inhibitor; Sodium-dependent serotonin transporter releasing agent | Approval | https://conductscience.org/library/genes/6532 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 4 | Norepinephrine transporter inhibitor; Sodium-dependent noradrenaline transporter releasing agent | Approval | https://conductscience.org/library/genes/6530 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 3 | Dopamine D2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 3 | Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 3 | Serotonin 2c (5-HT2c) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| TACR1 | Substance-P receptor | 3 | Neurokinin 1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/6869 | Drugs and targets |
| CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | 2 | Voltage-gated N-type calcium channel alpha-1B subunit blocker; Voltage-gated calcium channel modulator | Phase 3 | https://conductscience.org/library/genes/774 | Drugs and targets |
| CRHR1 | Corticotropin-releasing factor receptor 1 | 2 | Corticotropin releasing factor receptor 1 antagonist | Phase 2 | https://conductscience.org/library/genes/1394 | Drugs and targets |
| GRIN1 | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2902 | Drugs and targets |
| GRIN2A | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2903 | Drugs and targets |
1 to 10 of 64
See all 64 targetsTrials70
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00052078 | Child and Adolescent Anxiety Disorders (CAMS) | Phase 3 | 488 | 2017-04-25 | Anxiety Disorders, Social Phobia, Generalized Anxiety Disorder | SERTRALINE | Its record names the disease | ClinicalTrials.gov |
| NCT05030350 | Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD) | Phase 3 | 481 | 2025-10-21 | Social Anxiety Disorder | FASEDIENOL | Its record names the disease | ClinicalTrials.gov |
| NCT05011396 | PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2 | Phase 3 | 228 | 2025-11-24 | Social Anxiety Disorder | FASEDIENOL | Its record names the disease | ClinicalTrials.gov |
| NCT04754802 | PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge | Phase 3 | 224 | 2025-09-12 | Social Anxiety Disorder | FASEDIENOL | Its record names the disease | ClinicalTrials.gov |
| NCT00515879 | Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia | Phase 3 | 169 | 2015-07-23 | Social Anxiety Disorder | CYCLOSERINE | Its record names the disease | ClinicalTrials.gov |
| NCT02218736 | Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a | Phase 2 | 163 | 2019-01-08 | ANXIETY DISORDERS (or Anxiety and Phobic Neuroses) | ATICAPRANT | Its record names the disease | ClinicalTrials.gov |
| NCT02066792 | Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder | Early phase 1 | 152 | 2020-06-09 | Social Anxiety Disorder | CYCLOSERINE | Its record names the disease | ClinicalTrials.gov |
| NCT05193409 | A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder | Phase 2 | 151 | 2025-03-18 | Social Anxiety Disorder | BNC-210 | Its record names the disease | ClinicalTrials.gov |
| NCT00074802 | Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder | Phase 3 | 150 | 2017-06-14 | Social Anxiety Disorder | PAROXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT02432703 | A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder | Phase 2 | 150 | 2021-09-02 | Phobic Disorders | JNJ-42165279 | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 70
See all 70 trialsComparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| PH94B vs Placebo: Proportions (%) of CGI-I Responders in PH94B-treated and Placebo-treated Groups at the End of Visit 3 (Treatment) | 34 of 111 | 36 of 112 | 223 | NCT04754802 | Trial comparisons |
| PH94B vs Placebo: deaths from any cause | 0 of 111 | 0 of 112 | 223 | NCT04754802 | Trial comparisons |
| PH94B vs Placebo: serious adverse events | 0 of 111 | 0 of 112 | 223 | NCT04754802 | Trial comparisons |
| D-cycloserine-augmented CBT vs Placebo-augmented CBT: serious adverse events | 0 of 87 | 0 of 82 | 169 | NCT00515879 | Trial comparisons |
| JNJ-42165279 25 mg vs Placebo: deaths from any cause | 0 of 74 | 0 of 75 | 149 | NCT02432703 | Trial comparisons |
| JNJ-42165279 25 mg vs Placebo: serious adverse events | 2 of 74 | 0 of 75 | 149 | NCT02432703 | Trial comparisons |
| PH94B vs Placebo: Proportions (%) of CGI-I Responders in PH94B-treated and Placebo-treated Groups at the End of Visit 3 (Treatment) | 26 of 70 | 15 of 71 | 141 | NCT05011396 | Trial comparisons |
| CERC-501 vs Placebo: deaths from any cause | 0 of 45 | 0 of 44 | 89 | NCT02218736 | Trial comparisons |
| CERC-501 vs Placebo: serious adverse events | 0 of 45 | 0 of 44 | 89 | NCT02218736 | Trial comparisons |
| SPD503 vs PLACEBO: serious adverse events | 0 of 62 | 0 of 21 | 83 | NCT01470469 | Trial comparisons |
1 to 10 of 19
See all 19 comparisons in its trialsPapers from its trials55
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001247
GET https://conductscience.org/api/diseases/v1/MONDO_0001247/drugs?page=2